O-005Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. (2nd July 2019) - Harding, J; Cleary, J; Shapiro, G; Braña, I; Moreno, V; Quinn, D; Borad, M; Loi, S; Spanggaard, I; Stemmer, S; Dujka, M; Cutler, R; et al.